AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35090047
Drug: On-treatment LDH
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment LDH (elevated at weeks 6, 12, 18, and 24)
Trial: 35090047
Drug: On-treatment LDH
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment LDH (elevated at 6 weeks)
Trial: 35090047
Drug: On-treatment LDH
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment LDH (elevated at 12 weeks)
Trial: 33954805
Drug: Propofol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1 mg/kg)
Trial: 33933012
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone treatment starting with 60 mg daily tapered over 8 weeks
Trial: 33933012
Drug: No prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No prednisolone treatment (control group)
Trial: 32084431
Drug: GH-receptor antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: GH-receptor antagonist
Trial: 32379635
Drug: Lemon inhalation
RxNorm normalized name: LEMON
DrugBank: Lemon (DB10538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemon inhalation aromatherapy
Trial: 33659261
Drug: Empirical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical therapy
Trial: 35313227
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (800 mg IV in 150 mL normal saline over 5 minutes)
Trial: 35313227
Drug: Ibuprofen (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (800 mg IV in 150 mL normal saline over 5 minutes)
Trial: 35876124
Drug: Acarbose treatment
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose treatment
Trial: 35500536
Drug: Anle138b (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anle138b (150 mg per day)
Trial: 35323040
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of beta-lactam treatment
Trial: 35323040
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days of beta-lactam treatment
Trial: 34990854
Drug: Onsite buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onsite buprenorphine treatment initiation
Trial: 35240966
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 200 mg 3 times a day (600mg daily) plus conventional treatment
Trial: 34487750
Drug: Saroglitazar 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saroglitazar 2 mg
Trial: 36731585
Drug: Saroglitazar 4
RxNorm normalized name: Saroglitazar 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saroglitazar 4 mg
Trial: 36576555
Drug: Placebo (Isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Isotonic saline solution)
Trial: 34652335
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training (CT)
Trial: 34435694
Drug: Crisaborole ointment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crisaborole ointment, 2% (both QD and BID)
Trial: 35908682
Drug: Mechanical instrumentation
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical instrumentation without adjunct photodynamic therapy (Control)
Trial: 35908682
Drug: Mechanical instrumentation
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical instrumentation without adjunct photodynamic therapy (Control) in Group 2
Trial: 35908682
Drug: Mechanical instrumentation
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical instrumentation with adjunct photodynamic therapy (PDT) in Group 2
Trial: 32145440
Drug: Granulocyte‐Macrophage Colony
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte‐Macrophage Colony Stimulating Factor (GM‐CSF) 500 μg/day subcutaneously thrice weekly for three weeks, followed by a second administration after 3 months.
Trial: 32145440
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections thrice weekly for three weeks, followed by matching placebo injections after 3 months.
Trial: 32552264
Drug: Extended-release oral
RxNorm normalized name: Carbinoxamine Maleate Extended-Release Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release oral milrinone
Trial: 32838463
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (PI)
Trial: 32317229
Drug: Nighttime hydrating
RxNorm normalized name: Flonase Nighttime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nighttime hydrating eyelid gel (TDHA-AOX and HA), applied nightly to the upper and inner eyelids of the right eye for 2 weeks
Trial: 36453001
Drug: Narrative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative therapy
Trial: 32975739
Drug: D‐Fe (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐Fe (1000 IU/day vitamin D3 plus 27 mg/day iron)
Trial: 33827495
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (14 sessions of individual manual-based cognitive behavioral therapy and motivational interviewing (MOVE-I))
Trial: 34047872
Drug: 2% CHX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% CHX gel
Trial: 35550827
Drug: Treatment aimed
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment aimed at improving family communication
Trial: 34147142
Drug: Imatinib (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (800 mg loading dose on day 0 followed by 400 mg daily on days 1-9)
Trial: 32598812
Drug: Enoxaparin followed
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin followed by warfarin (1 mg/kg every 12 hours for 7 days, then warfarin to maintain INR 2.0-3.0)
Trial: 32598812
Drug: Rivaroxaban monotherapy
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban monotherapy (15 mg twice/day for 21 days, then 20 mg/day)
Trial: 32372290
Drug: Empagliflozin 10/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10/25 mg
Trial: 34762373
Drug: Moxibustion combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion combined with basic treatment
Trial: 33735709
Drug: Baclofen 75
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baclofen 75 mg/day
Trial: 35435089
Drug: Capacitive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capacitive and resistive electric transfer (CRET) therapy for 15 minutes on lower back
Trial: 35435089
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy for 15 minutes on lower back
Trial: 35635717
Drug: SHR6390 150-mg
RxNorm normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR6390 150-mg tablet under high-fat conditions
Trial: 35635717
Drug: SHR6390 150-mg
RxNorm normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR6390 150-mg tablet under fasting conditions
Trial: 32193541
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (tCS)
Trial: 33960445
Drug: Imepitoin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imepitoin (30 mg/kg BID)
Trial: 34130339
Drug: Enteric-coated formulations
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated formulations of aspirin
Trial: 35169373
Drug: Debridement, antibiotics,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debridement, antibiotics, irrigation and retention of prosthesis (DAIR)
Trial: 34161706
Drug: Azithromycin (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1-g single dose)
Trial: 36456992
Drug: Vildagliptin treatment
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin treatment
Trial: 34134825
Drug: Motivational Interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Interviewing (MI)‐enhanced parent‐teen behavior therapy
Trial: 33063705
Drug: Subcutaneous autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous autologous serum therapy
Trial: 33063705
Drug: Conventional intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intramuscular autologous serum therapy
Trial: 36451459
Drug: PN +
RxNorm normalized name: Penicillin G
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PN + EN (supplemental parenteral nutrition)
Trial: 32527290
Drug: Endotracheal surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endotracheal surfactant administration followed by low peak pressure ventilation (LPPSA)
Trial: 34986284
Drug: Immunosuppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive therapy plus eltrombopag (Group B)
Trial: 34986284
Drug: Immunosuppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive therapy (Group A)
Trial: 34554372
Drug: Exemestane (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane (25 mg o.d.)
Trial: 34554372
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg o.d.)
Trial: 32462216
Drug: Surgical needs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical needs survey administered by surgeons
Trial: 32046671
Drug: Motor-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motor-based treatment consistent with current best practices in speech therapy (40% of participants)
Trial: 32046671
Drug: Treatment incorporating
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment incorporating visual biofeedback (60% of participants)
Trial: 33602279
Drug: Nicotine supplementation
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine supplementation (2 mg)
Trial: 35502947
Drug: Topical Cannabidiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Cannabidiol (CBD)
Trial: 35390457
Drug: Topical Cannabidiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Cannabidiol (CBD) + Essential Oil (EO)
Trial: 34551471
Drug: Dexamethasone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (10 mg IV)
Trial: 35366811
Drug: Left lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left lateral position (Group L)
Trial: 33581481
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly sessions
Trial: 35428889
Drug: Teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20 mcg daily)
Trial: 35428889
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with teriparatide followed by denosumab
Trial: 36229342
Drug: Intramuscular ChAdOx1
RxNorm normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ChAdOx1 nCoV-19
Trial: 36229342
Drug: Intranasal ChAdOx1
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ChAdOx1 nCoV-19
Trial: 33406103
Drug: Wilderness programs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wilderness programs employing adventure therapy
Trial: 32948350
Drug: Sugar absorption
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar absorption test on days 4, 7, and 14 postpartum
Trial: 32032954
Drug: Best Medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best Medical Treatment (BMT)
Trial: 35013427
Drug: Post-treatment control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment control (individuals who can stop ART without viral load rebound)
Trial: 34506719
Drug: Laughter therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laughter therapy (LT) twice a week for 2 weeks
Trial: 34506719
Drug: Waiting-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting-list control (no treatment during the same period)
Trial: 33065774
Drug: Best supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best supportive care (no DAA therapy)
Trial: 35350983
Drug: ESP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESP block with 2 mg/kg levobupivacaine
Trial: 35350983
Drug: ESP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESP block with 2 mg/kg levobupivacaine and 5 μg/mL epinephrine
Trial: 35350983
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (L and LE)
Trial: 36093566
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg selenium as selenium-enriched yeast
Trial: 38215286
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg selenium as selenium-enriched yeast
Trial: 36093566
Drug: 300 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 μg selenium as selenium-enriched yeast
Trial: 36093566
Drug: 100, 200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100, 200, or 300 μg selenium as selenium-enriched yeast
Trial: 35280833
Drug: Melatonin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (20 mg daily for 5 days)
Trial: 33874683
Drug: Ultrafiltration on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrafiltration on top of standard therapy (diuretics, cardiotonic, vasodilator) with furosemide (40 mg) given immediately and 24 hours after ultrafiltration.
Trial: 33874683
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plan (diuretics, cardiotonic, vasodilator) without ultrafiltration.
Trial: 35038956
Drug: Narrow-band intense
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-band intense pulsed light (DPL) treatment at a wavelength of 500-600 nm, initiated 2 weeks post-surgery, given 3 times over a 4-week period.
Trial: 36355827
Drug: Iyengar yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iyengar yoga intervention self-administered over six weeks using an audio recording file
Trial: 32471423
Drug: Once-daily fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg via Ellipta inhaler
Trial: 32471423
Drug: Twice-daily budesonide/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily budesonide/formoterol (BUD/FOR) 400/12 μg via metered-dose inhaler plus once-daily tiotropium (TIO) 18 μg via HandiHaler
Trial: 32471423
Drug: Twice-daily budesonide/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily budesonide/formoterol (BUD/FOR) 400/12 μg plus once-daily tiotropium (TIO) 18 μg via HandiHaler
Trial: 36483622
Drug: Clopidogrel loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel loading dose (LD)
Trial: 35822553
Drug: Fenofibrate 200
RxNorm normalized name: fenofibrate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 200 mg once per day for 6 months
Trial: 33045224
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg once daily (15 mg for creatinine clearance <50 mL/min)
Trial: 33045224
Drug: Dose-adjusted warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-adjusted warfarin (target INR 2.0-3.0)
Trial: 35449839
Drug: Low-frequency nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency nerve therapy device
Trial: 35449839
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment methods (Control)
Trial: 32122870
Drug: Aceclofenac 100
RxNorm normalized name: aceclofenac 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aceclofenac 100 mg tablet b.i.d and enzyme supplements 250 mg b.i.d for 6 weeks
Trial: 32122870
Drug: Aceclofenac 100
RxNorm normalized name: aceclofenac 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aceclofenac 100 mg tablet b.i.d
Trial: 35304704
Drug: Iron deficiency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron deficiency defined as soluble transferrin receptor (sTfR) > 28.1 nmol/L
Trial: 35304704
Drug: Iron deficiency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron deficiency defined as ferritin < 45 µg/L
Trial: 35304704
Drug: Iron deficiency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron deficiency defined as ferritin < 30 µg/L
Trial: 35304704
Drug: Incidence rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Incidence rate (IR) for ferritin < 45 µg/L
Trial: 33442660
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment benefit
Trial: 32282418
Drug: BUP‐XR (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP‐XR (300 mg initial injection, followed by monthly doses of 300 mg or 100 mg)
Trial: 35510087
Drug: Clozapine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (up to 400 mg per day)
Trial: 32270440
Drug: Imeglimin (IMEG)
RxNorm normalized name: Fosaprepitant Dimeglumine
DrugBank: Imeglimin (DB12509)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Imeglimin (IMEG) 1500 mg twice daily with Metformin (MET) 850 mg twice daily
Trial: 35470909
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D3, 600,000 IU 5 days before surgery (Group B)
Trial: 33179323
Drug: Fremanezumab quarterly
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fremanezumab quarterly (675 mg at baseline)
Trial: 33179323
Drug: Fremanezumab monthly
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fremanezumab monthly (675 mg at baseline; 225 mg at Weeks 4 and 8)
Trial: 32273630
Drug: Abound (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abound (24 g) administered for 14 days through an enteral feeding tube
Trial: 32583478
Drug: Integrative Cognitive‐Affective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative Cognitive‐Affective Therapy (ICAT‐BED)
Trial: 35098531
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) N-acetylcysteine (NAC) in healthy volunteers with contrast
Trial: 35098531
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) NAC in patients with CKD3 receiving contrast
Trial: 35098531
Drug: Oral NAC
RxNorm normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral NAC in healthy volunteers
Trial: 33004272
Drug: Oxaliplatin treatment
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin treatment < 2 months prior to EVA/PCD analysis
Trial: 33809557
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied formulation containing components of natural moisturizing factor (NMF)
Trial: 39624908
Drug: Subcutaneous ICD
RxNorm normalized name: ICDMT
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous ICD (S-ICD)
Trial: 33044367
Drug: FEN (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEN (300 mg·d)
Trial: 33772303
Drug: Human growth
RxNorm normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human growth hormone (GH) injections (0.050 mg/kg/day) for 12 months
Trial: 33772303
Drug: Human growth
RxNorm normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human growth hormone (GH) injections
Trial: 34972770
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (individual cognitive behavioural therapy)
Trial: 35449368
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg olanzapine plus standard triple antiemetic therapy (aprepitant, tropisetron, dexamethasone)